Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Expected to Rise, Oppenheimer Analyst Says

Sensei Biotherapeutics (NASDAQ:SNSE) had its price objective hoisted by research analysts at Oppenheimer from $3.50 to $4.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Sensei Biotherapeutics in a research note on Friday.

Sensei Biotherapeutics Stock Up 18.0 %

NASDAQ:SNSE opened at $0.51 on Friday. The firm has a market cap of $12.78 million, a PE ratio of -0.43 and a beta of 0.16. Sensei Biotherapeutics has a 12 month low of $0.38 and a 12 month high of $1.94. The company’s 50-day moving average price is $0.47 and its two-hundred day moving average price is $0.49.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its earnings results on Friday, March 28th. The company reported ($0.27) EPS for the quarter, hitting the consensus estimate of ($0.27). On average, research analysts expect that Sensei Biotherapeutics will post -1.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI increased its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,575 shares of the company’s stock after buying an additional 35,575 shares during the period. National Bank of Canada FI owned 0.18% of Sensei Biotherapeutics worth $27,000 at the end of the most recent quarter. 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.